Progress in cardiovascular diseases · 2026
Association between gout and cardiovascular disease: A register-based cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pei Haolong, He Li, Wang Shuang, Mo Chunbao, Wang Jiangshui, Cui Xiang, Li Xia, Zheng Jing, Liang Fengchao
Аннотация
BACKGROUND: Gout and cardiovascular disease (CVD) are globally widespread diseases, yet evidence on their association in the Chinese population remains limited. We aimed to investigate the association between gout and the incident risk of CVD in a Chinese population.
METHODS: A register-based cohort study was conducted based on a city-wide health information platform in Shenzhen, China (2016-2022). We included individuals diagnosed with gout and free of CVD at baseline, and used the propensity score to select a 5-fold number of matched controls without gout. Electronic medical records and death registration were used to identify gout patients and CVD events. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between gout and the incident risk of CVD, including ischemic heart disease (IHD), stroke, and heart failure (HF).
RESULTS: We included 230,339 CVD-free gout patients and matched 1,055,509 controls. During a maximum follow-up of 5.7 years, a total of 5108 and 16,621 incident CVD in gout patients and the controls were recorded, with incidence rates of 9.82 and 6.24 per 1000 person-years, respectively. Compared with the controls, gout patients had a higher risk (HR: 1.27, 95% CI: 1.24 to 1.29) for the total CVD incidence. Subgroup analyses showed that women and younger patients (aged 18 to 44 years) with gout had higher relative risks of CVD than their counterparts (P for interaction ≤ 0.001).
CONCLUSION: We provide evidence that gout is associated with incident CVD risk, emphasizing the need for effective prevention and management strategies to mitigate CVD burden.
METHODS: A register-based cohort study was conducted based on a city-wide health information platform in Shenzhen, China (2016-2022). We included individuals diagnosed with gout and free of CVD at baseline, and used the propensity score to select a 5-fold number of matched controls without gout. Electronic medical records and death registration were used to identify gout patients and CVD events. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between gout and the incident risk of CVD, including ischemic heart disease (IHD), stroke, and heart failure (HF).
RESULTS: We included 230,339 CVD-free gout patients and matched 1,055,509 controls. During a maximum follow-up of 5.7 years, a total of 5108 and 16,621 incident CVD in gout patients and the controls were recorded, with incidence rates of 9.82 and 6.24 per 1000 person-years, respectively. Compared with the controls, gout patients had a higher risk (HR: 1.27, 95% CI: 1.24 to 1.29) for the total CVD incidence. Subgroup analyses showed that women and younger patients (aged 18 to 44 years) with gout had higher relative risks of CVD than their counterparts (P for interaction ≤ 0.001).
CONCLUSION: We provide evidence that gout is associated with incident CVD risk, emphasizing the need for effective prevention and management strategies to mitigate CVD burden.